INT68133

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.81
First Reported 1997
Last Reported 2011
Negated 2
Speculated 2
Reported most in Body
Documents 36
Total Number 38
Disease Relevance 15.37
Pain Relevance 9.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Fgf2) extracellular space (Fgf2) extracellular region (Fgf2)
nucleus (Fgf2) embryo development (Fgf2) cytoplasm (Fgf2)
Anatomy Link Frequency
fibroblast 9
neuronal 2
blood 2
nerve 2
MSCs 2
Fgf2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cytokine 241 100.00 Very High Very High Very High
bradykinin 18 100.00 Very High Very High Very High
qutenza 8 100.00 Very High Very High Very High
Glutamate 43 99.98 Very High Very High Very High
Nerve growth factor 227 99.88 Very High Very High Very High
metalloproteinase 118 99.80 Very High Very High Very High
Inflammation 170 99.60 Very High Very High Very High
Endep 3 99.06 Very High Very High Very High
dorsal root ganglion 2 99.00 Very High Very High Very High
COX-2 inhibitor 23 98.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 74 100.00 Very High Very High Very High
Adhesions 65 100.00 Very High Very High Very High
Necrosis 29 100.00 Very High Very High Very High
INFLAMMATION 192 99.60 Very High Very High Very High
Diabetes Mellitus 851 99.20 Very High Very High Very High
Disease 64 99.12 Very High Very High Very High
Ganglion Cysts 7 98.52 Very High Very High Very High
Pain 20 98.28 Very High Very High Very High
Nervous System Injury 14 98.04 Very High Very High Very High
Injury 204 97.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The cytoplasmatic and nuclear localization of the FGF-2 immunoreactivity [9] were taken into account in the discrimination of the neuronal and glial FGF-2 cell profiles.
Localization (localization) of FGF-2 in neuronal
1) Confidence 0.81 Published 2010 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2995486 Disease Relevance 0.09 Pain Relevance 0
It was reported that the FGF-2 synthesized in the tongue may be retrogradaly transported to the hypoglossal nucleus thus acting as a target derived neurotrophic factor.
Localization (transported) of FGF-2 in nucleus
2) Confidence 0.75 Published 2010 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2995486 Disease Relevance 0.06 Pain Relevance 0.10
Furthermore, a higher amount of FGF-2 was found in the nucleus of the reactive astrocytes of axotomized facial nuclei (Figure 4).
Localization (found) of FGF-2 in astrocytes
3) Confidence 0.75 Published 2010 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2995486 Disease Relevance 0.07 Pain Relevance 0
Observations such as reduced b-FGF and VEGF secretion and MMP-9 regulation reveals that COX-2 inhibitors possess the potential to be exploited in the in vivo model to better understand their benefits as an adjuvant to the currently available chemotherapy for KS.
Localization (secretion) of b-FGF associated with sarcoma, metalloproteinase and cox-2 inhibitor
4) Confidence 0.73 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.98 Pain Relevance 0.33
The cytoplasmatic and nuclear localization of the FGF-2 immunoreactivity [9] were taken into account in the discrimination of the neuronal and glial FGF-2 cell profiles.
Localization (localization) of FGF-2 in neuronal
5) Confidence 0.71 Published 2010 Journal J Brachial Plex Peripher Nerve Inj Section Body Doc Link PMC2995486 Disease Relevance 0.09 Pain Relevance 0
Immunohistochemically, red-colored cells indicating PKH26-positive MSCs were surrounded by a green color suggesting local secretion of bFGF and VEGF from the MSCs (Fig. 3A and B).


Localization (secretion) of bFGF
6) Confidence 0.68 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.47 Pain Relevance 0.21
MSCs have recently been shown to differentiate into multilineage cell types (8,9) and to secrete various cytokines, including bFGF and VEGF (10–13).
Localization (secrete) of bFGF in MSCs associated with cytokine
7) Confidence 0.68 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.79 Pain Relevance 0.30
In our study, bFGF and VEGF mRNA expressions in STZ-induced diabetic rats were upregulated in MSC-injected hind limb muscles, and MSCs maintained their viabilities and abilities to secrete bFGF and VEGF even 4 weeks after the transplantation.
Localization (secrete) of bFGF in limb muscles associated with diabetes mellitus
8) Confidence 0.68 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.32 Pain Relevance 0.16
The level of therapeutic vasculogenesis induced by MSC transplantation was similar to that by endothelial progenitor cell transplantation, as we previously reported (16), and the differentiation or incorporation of MSCs to vessels was not observed, suggesting that neovasculalization induced by transplantation would be mediated through the actions of angiogenic factors such as VEGF and bFGF secreted from MSCs, which would explain the improvement of NBF.
Localization (secreted) of bFGF in vessels
9) Confidence 0.68 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.35 Pain Relevance 0.07
Therefore, VEGF and bFGF secreted by the transplanted MSCs would additively exert angiogenic and neurotrophic actions.
Localization (secreted) of bFGF
10) Confidence 0.68 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.42 Pain Relevance 0.13
We used immunohistochemistry to examine spinal localization of the cytokines, interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and the growth factors, basic fibroblast growth factor (bFGF), and transforming growth factor-beta1 (TGF-beta) at 3, 14, and 35 days following sciatic cryoneurolysis or 6 days following chronic constriction injury as compared with normal, unoperated rats.
Spec (examine) Localization (localization) of bFGF in fibroblast associated with necrosis, cancer, eae, injury and cytokine
11) Confidence 0.65 Published 1997 Journal Brain Res. Section Abstract Doc Link 9219862 Disease Relevance 1.03 Pain Relevance 0.69
We used immunohistochemistry to examine spinal localization of the cytokines, interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and the growth factors, basic fibroblast growth factor (bFGF), and transforming growth factor-beta1 (TGF-beta) at 3, 14, and 35 days following sciatic cryoneurolysis or 6 days following chronic constriction injury as compared with normal, unoperated rats.
Spec (examine) Localization (localization) of basic fibroblast growth factor in fibroblast associated with necrosis, cancer, eae, injury and cytokine
12) Confidence 0.65 Published 1997 Journal Brain Res. Section Abstract Doc Link 9219862 Disease Relevance 1.03 Pain Relevance 0.69
Furthermore, colocalization of MSCs with VEGF and bFGF in the transplanted sites was confirmed.
Localization (colocalization) of bFGF in MSCs
13) Confidence 0.64 Published 2008 Journal Diabetes Section Abstract Doc Link PMC2570407 Disease Relevance 0.65 Pain Relevance 0.24
Scaffolds were characterized in vitro respect to their morphology, VEGF and bFGF release kinetics and bioactivity.
Localization (release) of bFGF
14) Confidence 0.62 Published 2010 Journal Biomaterials Section Abstract Doc Link 20381861 Disease Relevance 0.08 Pain Relevance 0.16
Of particular interest for future studies are those proteins that are not normalized (Fgf2 and Crybb2) or only partially normalized (Cp, Cryba3, Lgals3, Stat3) by insulin treatment, as these persistent changes reflect the limitations of insulin to restore the retina to a nondiabetic state.
Neg (not) Localization (normalized) of Fgf2 in retina
15) Confidence 0.61 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3020973 Disease Relevance 0.17 Pain Relevance 0
It can be speculated that diabetic conditions such as hyperglycemia and impaired local microcirculation might cause or require the transplanted MSCs to more strongly produce and secrete bFGF and VEGF.
Localization (secrete) of bFGF associated with hyperglycemia and diabetes mellitus
16) Confidence 0.60 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.65 Pain Relevance 0.11
Four weeks after the transplantation, MSCs maintained their viabilities and secreted angiogenic factors such as VEGF and bFGF at the injected sites.
Localization (secreted) of bFGF
17) Confidence 0.60 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.39 Pain Relevance 0.09
Local production and secretion of bFGF and VEGF.
Localization (secretion) of bFGF
18) Confidence 0.60 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.49 Pain Relevance 0.10
On the other hand, MSCs have been reported to secrete a wide array of cytokines, such as bFGF, VEGF, monocyte chemoattractant protein-1, and stem cell–derived factor-1 (12).
Localization (secrete) of bFGF in monocyte associated with cytokine
19) Confidence 0.60 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.27 Pain Relevance 0.14
In fact, MSC transplantation has been performed in the field of ischemic diseases, and it has been suggested that its plausible effects would be mediated largely through paracrine actions of locally released arteriogenic cytokines, including bFGF and VEGF (11,13,30).
Localization (released) of bFGF associated with disease and cytokine
20) Confidence 0.60 Published 2008 Journal Diabetes Section Body Doc Link PMC2570407 Disease Relevance 0.28 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox